Conclusions
PNH, fatigue, IVH
PNH
Understanding key clinical drivers of improvements in QoL and fatigue during C5 inhibitor therapy is important for developing appropriate management strategies for patients with PNH. In conclusion, these findings suggest that LDH level, as a surrogate parameter for IVH, is a key determinant of fatigue and QoL outcomes in patients with PNH. Treatment goals, particularly for C5-inhibitor naive patients, should focus on the improvement of LDH levels and subsequent avoidance of IVH, which C5 inhibitors have been demonstrated to successfully achieve.